May 20 (Reuters) – A preliminary review by the U.S. Food and
Drug Administration of Novo Nordisk A/S’s experimental
diabetes drug, IDegLira, questioned the interpretability of the
study findings and…
The post FDA staff question utility of Novo Nordisk combo diabetes drug appeared first on NASDAQ.